• +1-646-491-9876
    • +91-20-67278686

    Search

    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Pipeline Review, H2 2016

    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Pipeline Review, H2 2016

    • Report Code ID: RW0001506644
    • Category Pharmaceuticals
    • No. of Pages 45
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's, 'Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Pipeline Review, H2 2016', provides in depth analysis on Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted pipeline therapeutics.

    The report provides comprehensive information on the Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Report Scope

    - The report provides a snapshot of the global therapeutic landscape for Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21)
    - The report reviews Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents 2
    List of Tables 5
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) Overview 7
    Therapeutics Development 8
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Products under Development by Stage of Development 8
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Products under Development by Therapy Area 9
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Products under Development by Indication 10
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Pipeline Products Glance 11
    Late Stage Products 11
    Early Stage Products 12
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Products under Development by Companies 13
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Products under Development by Universities/Institutes 15
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Therapeutics Assessment 17
    Assessment by Monotherapy/Combination Products 17
    Assessment by Mechanism of Action 18
    Assessment by Route of Administration 19
    Assessment by Molecule Type 21
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Companies Involved in Therapeutics Development 23
    Cerecor Inc. 23
    Curevac AG 24
    Eisai Co., Ltd. 25
    Inovio Pharmaceuticals, Inc. 26
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Drug Profiles 27
    CV-9104 - Drug Profile 27
    Product Description 27
    Mechanism Of Action 27
    R&D Progress 27
    E-2072 - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    INO-5150 - Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    RBI-1033 - Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    Small Molecule for Neuropathic Pain - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment - Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    Vaccine to Target Prostate Specific Membrane Antigen for Renal Cell Carcinoma - Drug Profile 34
    Product Description 34
    Mechanism Of Action 34
    R&D Progress 34
    Vaccine to Target PSMA and TARP for Prostate Cancer - Drug Profile 35
    Product Description 35
    Mechanism Of Action 35
    R&D Progress 35
    Vaccine to Target PSMA, STEAP1 and PAP for Prostate Cancer - Drug Profile 36
    Product Description 36
    Mechanism Of Action 36
    R&D Progress 36
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Dormant Projects 37
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Discontinued Products 38
    Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Featured News & Press Releases 39
    Jul 27, 2015: Inovio Pharmaceuticals Initiates Clinical Trial of INO-5150 DNA Immunotherapy for Prostate Cancer 39
    Dec 16, 2013: CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment 39
    Mar 27, 2013: CureVac Initiates Phase IIb Clinical Trial Of mRNA-based Cancer Vaccine In Patients With Castration-resistant Prostate Cancer 40
    Nov 19, 2012: Experimental Drug Improves Memory In Mice With Multiple Sclerosis, Researchers Report 40
    Feb 02, 2011: Inovio's Dual-Antigen SynCon DNA Vaccine For Prostate Cancer Induces Robust Responses In Preclinical Trial 42
    Appendix 44
    Methodology 44
    Coverage 44
    Secondary Research 44
    Primary Research 44
    Expert Panel Validation 44
    Contact Us 44
    Disclaimer 45

    List of Tables

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Indication, H2 2016 10
    Comparative Analysis by Late Stage Development, H2 2016 11
    Comparative Analysis by Early Stage Products, H2 2016 12
    Number of Products under Development by Companies, H2 2016 13
    Products under Development by Companies, H2 2016 14
    Number of Products under Investigation by Universities/Institutes, H2 2016 15
    Products under Investigation by Universities/Institutes, H2 2016 16
    Assessment by Monotherapy/Combination Products, H2 2016 17
    Number of Products by Stage and Mechanism of Action, H2 2016 18
    Number of Products by Stage and Route of Administration, H2 2016 20
    Number of Products by Stage and Molecule Type, H2 2016 22
    Pipeline by Cerecor Inc., H2 2016 23
    Pipeline by Curevac AG, H2 2016 24
    Pipeline by Eisai Co., Ltd., H2 2016 25
    Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 26
    Dormant Projects, H2 2016 37
    Discontinued Products, H2 2016 38

    List of Figures

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Indication, H2 2016 10
    Comparative Analysis by Early Stage Products, H2 2016 12
    Assessment by Monotherapy/Combination Products, H2 2016 17
    Number of Products by Routes of Administration, H2 2016 19
    Number of Products by Stage and Routes of Administration, H2 2016 19
    Number of Products by Molecule Types, H2 2016 21
    Number of Products by Stage and Molecule Type, H2 2016 21
    Cerecor Inc.
    Curevac AG
    Eisai Co., Ltd.
    Inovio Pharmaceuticals, Inc.

    Request for Sample

    Report Url https://www.reportsweb.com//glutamate-carboxypeptidase-2-folate-hydrolase-1-or-prostate-specific-membrane-antigen-or-psma-or-pteroylpoly-gamma-glutamate-carboxypeptidase-or-cell-growth-inhibiting-gene-27-protein-or-folh1-or-ec-3-4-17-21-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//glutamate-carboxypeptidase-2-folate-hydrolase-1-or-prostate-specific-membrane-antigen-or-psma-or-pteroylpoly-gamma-glutamate-carboxypeptidase-or-cell-growth-inhibiting-gene-27-protein-or-folh1-or-ec-3-4-17-21-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//glutamate-carboxypeptidase-2-folate-hydrolase-1-or-prostate-specific-membrane-antigen-or-psma-or-pteroylpoly-gamma-glutamate-carboxypeptidase-or-cell-growth-inhibiting-gene-27-protein-or-folh1-or-ec-3-4-17-21-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments